BNP Paribas Financial Markets’s Zentalis Pharmaceuticals ZNTL Stock Holding History

BNP Paribas Financial Markets’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.5K	Sell	12,479 -458,959	-97%	-$1.83M	﹤0.01%	4795
2026 Q1	$1.1M	Buy	471,438 +52,071	+12%	+$134K	﹤0.01%	3070
2025 Q4	$566K	Buy	419,367 +260,432	+164%	+$379K	﹤0.01%	3500
2025 Q3	$240K	Sell	158,935 -14,549	-8%	-$21.8K	﹤0.01%	3923
2025 Q2	$201K	Buy	173,484 +102,661	+145%	+$135K	﹤0.01%	3770
2025 Q1	$113K	Sell	70,823 -105,469	-60%	-$227K	﹤0.01%	3991
2024 Q4	$534K	Buy	+176,292	New	+$578K	﹤0.01%	3258
2022 Q4	–	Sell	-76,564	Closed	-$1.66M	–	4690
2022 Q3	$1.66M	Buy	+76,564	New	+$2.09M	﹤0.01%	2095

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's ZNTL Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Zentalis Pharmaceuticals (ZNTL) stake by 97% in Q2 2026, selling an estimated $1.83M and leaving 12,479 shares worth $60.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4795.

BNP Paribas Financial Markets first reported a position in ZNTL in Q3 2022 and has held it in 8 quarters since. The position peaked at $1.66M in Q3 2022. 103 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

BNP Paribas Financial Markets held 12,479 shares of Zentalis Pharmaceuticals worth $60.5K as of Q2 2026.
BNP Paribas Financial Markets sold 458,959 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.83M.
Zentalis Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4795 holding.
BNP Paribas Financial Markets first reported a position in Zentalis Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
BNP Paribas Financial Markets's Zentalis Pharmaceuticals position peaked at $1.66M in Q3 2022.
103 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.